Natural Cycles
-26%
est. 2Y upside i
Natural Cycles is the only app to be FDA cleared as birth control. Natural and non-invasive we offer a brand new, revolutionary birth control option that’s given millions of individuals the power to go hormone-free.
Rank
#3421
Sector
Femtech
Est. Liquidity
~4Y
Data Quality
Data: LowEquity upside is expected negative (-26%) over 2 years due to stale valuation, high preference overhang, and strong competitive threats from Big Tech.
Last updated: July 3, 2026
IPO window opens with Oura success; revenue grows 40%+ but missing base makes uncertain; diluted upside 65%.
Steady subscription growth, multiple contracts, but competition limits expansion; diluted upside 5%.
Big Tech integration erodes market share, down round below $107M; common stock worthless after preference.
Preference Stack Risk
severeFunding Intensity
57%$107M in preferred stock over a $189M valuation (56.6% overhang), common shareholders only participate above $107M.
Dilution Risk
moderateCompany may raise another private round before IPO; assume 15% dilution from current share count.
Secondary Liquidity
limited$53M secondary transaction in June 2026 provides some liquidity, but employee shares may not be included.
Questions to Ask at the Interview
Strategic questions based on Natural Cycles's data — designed to show you've done your homework.
- 1
“How does Natural Cycles plan to defend against Apple's cycle tracking integration?”
- 2
“What are the unit economics and customer acquisition cost for the subscription model?”
- 3
“How does the June 2026 secondary transaction affect employee equity liquidity and valuation?”
Community
Valuation Sentiment
Our model estimates -26% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.